Hepatitis C News

BOSTON — Treatment with sofosbuvir-based direct-acting antivirals demonstrated durable sustained virologic response up to 5 years among pediatric patients with hepatitis C virus, according to findings presented at The Liver Meeting.

BOSTON — In the absence of cirrhosis, no specific precautions are needed for patients with SARS-CoV-2 infection and a history of hepatitis C virus, according to findings presented at The Liver Meeting.

BOSTON — After 12 weeks of treatment with sofosbuvir/velpatasvir in combination with tenofovir alafenamide, patients with hepatitis C virus and hepatitis B virus co-infection demonstrated high rates of sustained virologic response.

BOSTON — Direct-acting antiviral therapy for hepatitis C virus-related hepatocellular carcinoma significantly improves overall survival, but only one in four patients receive therapy, even with insurance, according to a researcher.

The CDC this week recommended hepatitis C testing for all infants or children who were perinatally exposed to the virus by a pregnant person with a current or probable HCV infection.

Alcohol use at initiation of direct-acting antiviral treatment was not associated with reduced odds for achieving sustained virologic response among veterans with chronic hepatitis C virus infection, according to data in JAMA Network Open.

An automated best practice advisory within the electronic health record can improve infectious disease screening in patients with autoimmune and rheumatic conditions, according to data published in Arthritis Care & Research.

On Friday, clinicians and researchers across the world recognized World Hepatitis Day as an opportunity to honor the “more than a million lives lost to hepatitis” every year and redouble national efforts to stop its spread.

In new guidance, the CDC recommended that the two-step testing process for hepatitis C virus be completed in one visit, eliminating the need for multiple visits, which often leads to incomplete testing.

Research demonstrated that hepatocellular carcinoma surveillance is cost-effective at a lower incidence threshold of 0.7% in virologically cured patients with hepatitis C virus, underscoring the need to update clinical guidelines.